Evocalcet: A New Oral Calcimimetic for Dialysis Patients With Secondary Hyperparathyroidism

Patients with chronic kidney disease often develop secondary hyperparathyroidism (SHPT), marked by high levels of circulating parathyroid hormone (PTH) and increased risk of morbidity and mortality. Patients with SHPT are treated with a therapeutic combination that commonly includes calcimimetics, w...

Descripción completa

Detalles Bibliográficos
Autores principales: Akizawa, Tadao, Ikejiri, Kazuaki, Kondo, Yuichiro, Endo, Yuichi, Fukagawa, Masafumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2019
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317959/
https://www.ncbi.nlm.nih.gov/pubmed/31486206
http://dx.doi.org/10.1111/1744-9987.13434

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317959/
https://www.ncbi.nlm.nih.gov/pubmed/31486206
http://dx.doi.org/10.1111/1744-9987.13434

Ejemplares similares